Evidence map›Paper›PMID 39114023›Full record

ArticleHeliyon2024

Using a genetic backpropagation neural network model for credit risk assessment in the micro, small and medium-sized enterprises.

Binhao Chen, Weifeng Jin, Huajing Lu

Abstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Binhao ChenZhejiang Chinese Medical University, Hangzhou, 310053, China.
Weifeng JinZhejiang Chinese Medical University, Hangzhou, 310053, China.
Huajing LuNingbo University of Finance and Economics, Ningbo, 315175, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In China, with the "Double Carbon" goal within reach, Micro, Small and Medium-sized Enterprises (MSMEs) emerge as pivotal contributors to economic advancement. However, they are now confronted with the imperative of transitioning towards green and low-carbon practices. To facilitate the attainment of peak carbon dioxide emissions and carbon neutrality, a refined approach is imperative. This entails precise capital allocation, enhanced financial services, streamlined management, and robust risk mitigation strategies. Consequently, conducting thorough credit risk assessments for MSMEs becomes a crucial endeavor. However, obtaining substantial loans for them proves challenging due to their elusive credit ratings and potential defaults. To address this issue, this study leverages machine learning and intelligent optimization algorithms to construct a classification model for default and credit ratings of MSMEs, utilizing their daily invoice data. Specifically, twelve indicators pertaining to default and credit ratings are extracted. Subsequently, Principal Component Analysis is employed to reduce dimensionality and synthesize all pertinent information. Following this, the Genetic Algorithm-based Back Propagation Neural Network (GA-BPNN) is utilized to delineate the relationship between indicators and default, as well as credit rating, respectively. The results indicate a prediction accuracy of 0.92 for default risk and 0.86 for credit rating. This underscores the efficacy of GA-BPNN in effectively classifying the underlying default risk and credit ratings of MSMEs, offering a promising approach for decision-making.

Indexed as

Credit ratingDecision-making approachDefault riskGenetic back propagation neural network (GA-BPNN)MicroSmall and Medium Enterprises (MSMEs)

Identifiers

PMID39114023
PMCPMC11303992

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.